Estimating the cost-effectiveness of treatment for prevention of thromboembolic events in at-risk adults with non-valvular atrial fibrillation by Bellone, Marco et al.
11© 2018 The Authors. Published by SEEd srl. This is an open access article under the CC BY-NC 4.0 license (https://creativecommons.org/licenses/by-nc/4.0)
IntroductIon
Atrial fibrillation (AF) represents the most prevalent form of cardiac arrhythmia. In Eu-
rope and the US 1 in 4 middle-aged adults will develop AF and it is estimated that by 2030 in 
Europe there will be 14-17 million of AF patients with 120,000-215,000 new cases per year 
[1]. In Italy, a recent observational study estimated a prevalence of AF equal to 1.7% for a 
total of 1,036,448 cases [2]. AF is independently associated with a higher risk of all-cause and 
cardiovascular mortality, the latter due to sudden death, heart failure, and stroke. Compared 
to subjects without AF, stroke, which is the main complication of AF, is nearly five times 
more frequent in subjects with AF [3]. Ischemic stroke due to AF is associated with higher 
mortality and worse functional outcomes than non AF-associated ischemic stroke, and AF is 
responsible for 20-30% of ischemic stroke [1].
In this context, the prevention of stroke represents a primary goal in the management of 
patients with AF and a high thromboembolic risk. The current European guidelines recom-
mend to evaluate the annual incidence of cerebral stroke using the CHA2DS-VASc score 
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AbstrAct
INTRODUCTION: The direct oral anticoagulants (DOACs) have demonstrated a more predictable effect and a more favor-
able risk-benefit ratio compared to the standard oral anticoagulant treatment for the prevention of stroke in patients with 
non-valvular atrial fibrillation (NVAF).
AIM: To estimate the efficiency of DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban vs. warfarin), in the preven-
tion of clinical events in adult patients with NVAF.
METHODS: A deterministic incremental cost-effectiveness analysis was performed to evaluate the avoidance of a clini-
cal event and the incremental cost per avoided clinical event, in a hypothetical population of 100,000 adult patients with 
NVAF, over 1-year period. In the absence of head-to-head comparison trials between DOACs, relative risks were derived 
from a network meta-analysis. Clinical events considered include stroke/systemic embolism (SE) and major bleeding. Only 
direct health costs related to the management of clinical events and drug acquisition costs were considered. Clinical event 
management costs were derived from literature and from the Diagnosis Related Group (DRG) tariffs. Net annual treatment 
costs were calculated based on the daily dose reported in the Summary of Product Characteristics (SPCs) and the ex-factory 
price of each drug.
RESULTS: Among DOACs, apixaban was associated with the highest net clinical benefit with 1,064 avoided events over 
1 year, compared to warfarin (728 major bleeding events and 336 strokes/SE). Furthermore, apixaban is the most efficient 
DOAC, with a cost per avoided event equal to € 16,672 vs. warfarin (€ 24,120 for edoxaban 60 mg, € 36,777 for dabigatran 
150 mg).
CONCLUSION: Apixaban has the highest potential net clinical benefit among DOACs for patients with NVAF and the 
least incremental cost per avoided event for the Italian National Health Service.
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which stratifies patients with thromboembolic risk based on gender (female have a higher 
risk) and the presence of congestive heart failure, hypertension, age ≥ 65 years, diabetes, pre-
vious stroke or transient ischemic attack (TIA) or thromboembolism, and vascular disease [1]. 
Oral anticoagulation (OAC) is not indicated in absence of clinical risk factors (CHA2DS2-
VASc = 0 – includes women without other stroke risk factors), while is highly recommended 
in subjects with AF and CHA2DS2-VASC ≥ 2 (if men) or ≥ 3 (if women). OAC has potential 
clinical net benefit also in patients with one risk factor, therefore it should be considered in 
men with CHA2DS2-VASC = 1 and women with CHA2DS2-VASC = 2 [1].
The traditional standard oral anticoagulant treatment is represented by warfarin and other 
vitamin K antagonists (VKAs) which have demonstrated to reduce the risk of stroke by 64% 
compared with placebo [4]. However, VKA therapy presents some limitations, such as in-
teractions with drugs and food, the need for regular dosage adjustment based on periodic 
INR (International Normalized Ratio) monitoring, and the risk of major bleeds, which could 
reduce patient compliance [5]. During the last years new direct anticoagulant drugs which 
overcome some of these limitations have been developed.
The direct oral anticoagulants (DOACs) have been approved for the prevention of stroke 
in patients with NVAF (non-valvular AF) thereby excluding AF patients with mechanical 
heart valves or moderate to severe mitral stenosis. The DOACs currently indicated are factor 
Xa inhibitors apixaban, edoxaban, and rivaroxaban; and the direct thrombin inhibitor dabiga-
tran; they have demonstrated a more predictable effect and a more favorable risk-benefit ratio, 
without the need for INR monitoring, compared to standard therapy. In phase III trials (Table 
I), and in several indirect comparisons, both the individual DOACs and the entire class were 
considered non-inferior, or superior, to warfarin in the reduction of stroke, systemic embolism 
(SE), intracranial bleeding, and mortality [6-14] and are recommended in the first-line treat-
ment of patient with AF in preference to VKAs [1].
When selecting a DOAC for stroke prevention in AF, several factors must be considered, 
including the evaluation of the net clinical benefit, since the anticoagulant activity, which al-
lows reducing ischemic stroke and systemic embolism, must be balanced against an increased 
risk of hemorrhagic events.
Despite the overall clinical net benefit of DOACs compared with VKAs, mainly due to 
reduced incidence of intracranial bleeding, there are important differences in the safety and 
efficacy profile among DOACs. A recent systematic review and meta-analysis of RCT aimed 
to identify the most effective, safe, and cost-effective anticoagulant for stroke prevention in 
AF, demonstrated that apixaban seems to have the best risk benefit ratio [12,15].
The results, obtained from 23 RCTs, confirmed that apixaban 5 mg bis in die (BID – twice 
daily), dabigatran 150 mg BID, edoxaban 60 mg quaque die (QD – once daily), and rivaroxa-
ban 20 mg QD all reduce the risk of stroke or systemic embolism, major bleeding, intracranial 
bleeding, and all-cause mortality compared with warfarin. Of the available DOACs, apixaban 
offers the best balance between efficacy and safety since it was ranked the best intervention 
for many of the outcomes evaluated, including stroke or SE, myocardial infarction, major 
bleeding, and all-cause mortality [12].
Another network meta-analysis, which included seven trials (for a total of 52,701 patients), 
showed that, while apixaban 5 mg BID and dabigatran 150 mg BID proved to be equally supe-
rior to warfarin in preventing stroke + SE, apixaban was associated with fewer major bleeding 
events than dabigatran 150 mg BID (OR = 0.73; CI95%: 0.57-0.93) and rivaroxaban 20 mg 
QD (OR = 0.66; CI95%: 0.52-0.84) and fewer drug discontinuations than dabigatran 150 mg 
BID (OR = 0.64; CI95%: 0.52-0.78) and 110 mg BID (OR = 0.66; CI95%: 0.54-0. 81). Since 
the ENGAGE AF-TIMI was ongoing, data for edoxaban were inconclusive [9].
Edoxaban was included in a network meta-analysis of the four phase III RCTs with the 
aim to assess the relative efficacy and safety of DOACs [11]. The results show that apixaban 
has a better safety profile in comparison to the other DOACs. Indeed it was associated with 
fewer bleeding events of any type (OR = 0.81; CI95%: 0.89-0.74) than edoxaban 60 mg QD 
and less major and GI bleeds than dabigatran 150 mg (major: OR = 0.75; CI95%: 0.61-0.90; 
GI: OR = 0.59; CI95%: 0.41-0.82) and rivaroxaban (major: OR = 0.67; CI95%: 0.82-0.55; 
GI: OR = 0.58; CI95%: 0.86-0.43) [11]. Finally, an indirect comparison analysis based on the 
phase III clinical trials found that there were no significant efficacy differences between edox-
aban 60 mg QD and apixaban 5 mg BID, but apixaban was associated with lower clinically 
relevant non-major bleeding (HR = 0.79; CI95%: 0.70-0.90) and gastrointestinal bleeding 
(HR = 0.72; CI95%: 0.55-0.96) [14]. Regarding gastrointestinal bleeding, the meta-analysis 
from Ruff et al., which compared DOACs as a class with warfarin, showed that DOACs are 
associated with significant reductions in stroke, intracranial hemorrhage and mortality, a simi-
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which stratifies patients with thromboembolic risk based on gender (female have a higher 
risk) and the presence of congestive heart failure, hypertension, age ≥ 65 years, diabetes, pre-
vious stroke or transient ischemic attack (TIA) or thromboembolism, and vascular disease [1]. 
Oral anticoagulation (OAC) is not indicated in absence of clinical risk factors (CHA2DS2-
VASc = 0 – includes women without other stroke risk factors), while is highly recommended 
in subjects with AF and CHA2DS2-VASC ≥ 2 (if men) or ≥ 3 (if women). OAC has potential 
clinical net benefit also in patients with one risk factor, therefore it should be considered in 
men with CHA2DS2-VASC = 1 and women with CHA2DS2-VASC = 2 [1].
The traditional standard oral anticoagulant treatment is represented by warfarin and other 
vitamin K antagonists (VKAs) which have demonstrated to reduce the risk of stroke by 64% 
compared with placebo [4]. However, VKA therapy presents some limitations, such as in-
teractions with drugs and food, the need for regular dosage adjustment based on periodic 
INR (International Normalized Ratio) monitoring, and the risk of major bleeds, which could 
reduce patient compliance [5]. During the last years new direct anticoagulant drugs which 
overcome some of these limitations have been developed.
The direct oral anticoagulants (DOACs) have been approved for the prevention of stroke 
in patients with NVAF (non-valvular AF) thereby excluding AF patients with mechanical 
heart valves or moderate to severe mitral stenosis. The DOACs currently indicated are factor 
Xa inhibitors apixaban, edoxaban, and rivaroxaban; and the direct thrombin inhibitor dabiga-
tran; they have demonstrated a more predictable effect and a more favorable risk-benefit ratio, 
without the need for INR monitoring, compared to standard therapy. In phase III trials (Table 
I), and in several indirect comparisons, both the individual DOACs and the entire class were 
considered non-inferior, or superior, to warfarin in the reduction of stroke, systemic embolism 
(SE), intracranial bleeding, and mortality [6-14] and are recommended in the first-line treat-
ment of patient with AF in preference to VKAs [1].
When selecting a DOAC for stroke prevention in AF, several factors must be considered, 
including the evaluation of the net clinical benefit, since the anticoagulant activity, which al-
lows reducing ischemic stroke and systemic embolism, must be balanced against an increased 
risk of hemorrhagic events.
Despite the overall clinical net benefit of DOACs compared with VKAs, mainly due to 
reduced incidence of intracranial bleeding, there are important differences in the safety and 
efficacy profile among DOACs. A recent systematic review and meta-analysis of RCT aimed 
to identify the most effective, safe, and cost-effective anticoagulant for stroke prevention in 
AF, demonstrated that apixaban seems to have the best risk benefit ratio [12,15].
The results, obtained from 23 RCTs, confirmed that apixaban 5 mg bis in die (BID – twice 
daily), dabigatran 150 mg BID, edoxaban 60 mg quaque die (QD – once daily), and rivaroxa-
ban 20 mg QD all reduce the risk of stroke or systemic embolism, major bleeding, intracranial 
bleeding, and all-cause mortality compared with warfarin. Of the available DOACs, apixaban 
offers the best balance between efficacy and safety since it was ranked the best intervention 
for many of the outcomes evaluated, including stroke or SE, myocardial infarction, major 
bleeding, and all-cause mortality [12].
Another network meta-analysis, which included seven trials (for a total of 52,701 patients), 
showed that, while apixaban 5 mg BID and dabigatran 150 mg BID proved to be equally supe-
rior to warfarin in preventing stroke + SE, apixaban was associated with fewer major bleeding 
events than dabigatran 150 mg BID (OR = 0.73; CI95%: 0.57-0.93) and rivaroxaban 20 mg 
QD (OR = 0.66; CI95%: 0.52-0.84) and fewer drug discontinuations than dabigatran 150 mg 
BID (OR = 0.64; CI95%: 0.52-0.78) and 110 mg BID (OR = 0.66; CI95%: 0.54-0. 81). Since 
the ENGAGE AF-TIMI was ongoing, data for edoxaban were inconclusive [9].
Edoxaban was included in a network meta-analysis of the four phase III RCTs with the 
aim to assess the relative efficacy and safety of DOACs [11]. The results show that apixaban 
has a better safety profile in comparison to the other DOACs. Indeed it was associated with 
fewer bleeding events of any type (OR = 0.81; CI95%: 0.89-0.74) than edoxaban 60 mg QD 
and less major and GI bleeds than dabigatran 150 mg (major: OR = 0.75; CI95%: 0.61-0.90; 
GI: OR = 0.59; CI95%: 0.41-0.82) and rivaroxaban (major: OR = 0.67; CI95%: 0.82-0.55; 
GI: OR = 0.58; CI95%: 0.86-0.43) [11]. Finally, an indirect comparison analysis based on the 
phase III clinical trials found that there were no significant efficacy differences between edox-
aban 60 mg QD and apixaban 5 mg BID, but apixaban was associated with lower clinically 
relevant non-major bleeding (HR = 0.79; CI95%: 0.70-0.90) and gastrointestinal bleeding 
(HR = 0.72; CI95%: 0.55-0.96) [14]. Regarding gastrointestinal bleeding, the meta-analysis 
from Ruff et al., which compared DOACs as a class with warfarin, showed that DOACs are 
associated with significant reductions in stroke, intracranial hemorrhage and mortality, a simi-
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ajor bleeding
1.09
1.60 (1.48, 
1.19‑1.86; 
p <
0.001)
1.13 (1.04, 
0.82‑1.33; 
p =
 0.74)
0.86
0.76 (0.89, 
0.70‑1.15; p =
 0.37)
1.24
2.00 (1.61; 
1.30‑1.99; p <
 
0.001)
1.23
1.51 (1.23, 
1.02‑1.50; p =
 0.03)
0.82 (0.67, 
0.53‑0.83; 
p <
0.001)
M
yocardial 
infarction
0.64
0.81 (1.27, 
0.94‑1.71; 
p =
 0.12)
0.82 (1.29, 0.96‑ 
1.75; p =
 0.09)
0.61
0.53 (0.88, 
0.66‑1.17; p =
 0.37)
1.12
0.91 (0.81; 
0.63‑1.06; p =
 0.12)
0.75
0.70 (0.94, 
0.74‑1.19; p =
 0.60)
0.89 (1.19, 
0.95‑1.49; p =
 0.13)
D
eath from
 any 
cause
4.13
3.64 (0.88, 
0.77‑1.00; 
p =
 0.051)
3.75 (0.91, 
0.80‑1.03; 
p =
 0.13)
3.94
3.52 (0.89, 
0.80‑0.99; 
p =
 0.047)
2.21
1.87 (0.85; 
0.70‑1.02; p =
 0.07)
4.35
3.99 (0.92, 
0.83‑1.01; p =
 0.08)
3.80 (0.87, 
0.79‑0.96; 
p =
 0.006)
Tab
le i. Sum
m
ary of the phase III R
C
Ts. M
odified from
 [1]
1 For non‑inferiority and superiority
2 For non‑inferiority
3 For superiority
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lar risk of major bleeding, and a higher risk of GI bleeding. However, individual comparisons 
show that, unlike dabigatran 150 mg, rivaroxaban and edoxaban 60 mg, apixaban is associ-
ated with a decreased risk of gastrointestinal bleeding [13].
In a recent consensus document, published on the European Heart Journal [16,17], the 
Authors give suggestions, based on the results of phase III trials or, if unavailable, on expert 
opinion, for chosing the drug and/or dose for particular subgroups of patients. In particular, 
apixaban 5 mg twice daily is recommended as first choice for patients with AF and high risk 
of gastrointestinal bleeding, chronic kidney failure (creatinine clearance 30-49 ml/min) or 
older than 75 years .
Aim of this paper is to estimate the efficiency of DOACs (apixaban, dabigatran, edoxaban, 
and rivaroxaban vs. warfarin) in the prevention of clinical events in adult patients with NVAF 
from the perspective of the Italian NHS.
Methods
A deterministic incremental cost-effectiveness analysis was performed in Microsoft Ex-
cel®. The effectiveness side is defined as the avoidance of a clinical event, which may be 
either a stroke/SE (primary efficacy indicator) or a major bleed (primary safety indicator). The 
overall cost-effectiveness indicator is the incremental cost per avoided clinical event, evalu-
ated in a hypothetical population of 100,000 adult patients with NVAF, with one or more risk 
factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; 
diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II), (Figure 1). Time horizon is 
one year.
Clinical input
Clinical events considered in the analysis include the primary efficacy outcome of stroke/
SE and the primary safety outcome of major bleeding. In the absence of RCTs that directly 
compare apixaban with other DOACs, relative risks were derived from the network meta-
analysis (NMA) by Lip et al. [18]. NMA is a type of analysis widely used in pharmacoeco-
nomics for overcoming the lack of head-to-head trials, as reported by the ISPOR Task Force 
on Indirect Treatment Comparisons Good Research Practices [19] and the NICE guide to the 
methods of technology appraisal [20].
Lip et al. conducted a network meta-analysis including data from phase III RCTs on full 
dose apixaban, edoxaban, dabigatran, and rivaroxaban (Table I) vs. warfarin, to assess the 
relative efficacy and safety in stroke prevention of apixaban vs. other DOACs [18], both on 
the overall evaluated population and in three subgroups: i) patients with CHADS2 score ≥ 2; 
ii) use in secondary prevention (patients with previous stroke or TIA); iii) patients with high 
quality anticoagulation control with warfarin [18]. The results of the comparison of DOACs 
with warfarin were consistent with the results from the RCTs and broadly similar in the overall 
and subgroup results, with apixaban showing the most favorable efficacy and safety profile.
The current analysis is conducted as a series of pairwise comparisons between DOACs 
and warfarin, using the HRs of the annual risk of stroke/SE and major bleeding (Table II) [18].
In RCTs and NMA analyses, data on 
hemorrhagic strokes are included as part of 
stroke/SE and major bleeding. In order to 
avoid double-counting these events in the 
calculation of the net clinical benefit, the 
number of hemorrhagic strokes was sub-
tracted from major bleeding events counts 
(Table II). Similarly, gastrointestinal 
bleeds, included in major bleeding counts, 
were not considered as separate clinical 
events.
Cost input
Since the analysis was conducted from 
the perspective of the Italian NHS, only di-
rect health costs related to acquisition and 
monitoring of drugs and to management of 
episodes of stroke/SE and major bleeding 
events were considered.Figure 1. Structure of the cost calculation
Warfarin annual 
risk (%) [6]
hr vs. warfarin (Ci95%) [18]
apixaban 
5 mg BiD
Dabigatran 
150 mg BiD
rivaroxaban 
20 mg QD
Edoxaban 
60 mg QD
Stroke/SE 1.60 0.79 (0.66‑0.95) 0.65 (0.52‑0.81) 0.87 (0.74‑1.03) 0.87 (0.75‑1.02)
Major bleeding 3.09 0.69 (0.60‑0.80) 0.93 (0.81‑1.07) 1.05 (0.91‑1.2) 0.80 (0.71‑0.91)
Hemorragic stroke 0.47 0.51 (0.35‑0.74) 0.26 (0.13‑0.48) 0.59 (0.39‑0.89) 0.55 (0.39‑0.78)
Table ii. HR vs. warfarin used in the analyses
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Event management costs
Clinical event management costs over 1 year include all costs incurring during the acute 
period and any long-term maintenance costs. The annual cost attributed to a major bleed is ap-
proximated with the corresponding DRG-based tariff paid to hospitals by the National Health 
Service [21], in particular DRG 174 – GI major bleed was used (€ 3,317 per event). Stroke/
SE management cost derive from data reported in an observational study conducted on 411 
Italian stroke survivors, followed up for 12 months [22]. In this study, the total direct health-
care costs amounted to an average € 11,747 per stroke survivor, considering both ischemic 
and hemorrhagic stroke.
Drug costs
Drug acquisition costs were taken from the Italian Official Gazette [23,24] and accord-
ing with the current legislation apixaban (Eliquis®, Pfizer/Bristol-Myers Squibb), dabigatran 
(Pradaxa®, Boehringer Ingelheim), rivaroxaban (Xarelto®, Bayer Pharma/Janssen Pharma-
ceuticals) and edoxaban (Lixiana®, Daiichi-Sankyo) are valued using ex-factory prices, while 
retail price was considered for warfarin (Coumadin®, Bristol-Myers Squibb). Net annual treat-
ment costs were calculated based on the daily dose reported in the SPCs of each drug (Table 
III).
For warfarin treated patients an annual INR monitoring cost of € 380 was considered, as 
reported by Pradelli et al. [25] in which the annual cost reported by Mennini et al. [26] was 
actualized to 2013 values.
sensitivity analysis
A probabilistic sensitivity analysis (PSA) was performed to take into account uncertainties 
in the input parameters. This was obtained by a Montecarlo simulation: the simulation was 
repeated 1,000 times sampling all the key parameters from appropriate distributions fitted 
on the available mean and standard error (SE). The PSA was conducted on the hazard ratios 
(HRs) for each event considered (i.e. stroke/SE, major bleeding, hemorrhagic stroke). For the 
PSA, the natural logarithm was sampled from a normal distribution fitted on the confidence 
intervals reported. The parameters and the distributions used for the PSA are reported in Ap-
pendix A.
results
Figure 2 shows the number of stroke/SE and major bleeding events avoided and the net 
clinical benefit achieved with each DOAC compared to warfarin for the treatment of a hypo-
thetical cohort of 100,000 patients with NVAF, with one or more risk factors over 1-year pe-
Daily dose Package
Ex‑factory 
price (€/day)
acquisition 
legal price 
discount (‑5%)
legal price 
discount 
(‑5%)
Confidential 
discount
Price 
volume 
agreement
Apixaban 5 mg BID 60 tablets 5 mg 2.23 Yes P Yes Yes
Dabigatran 150 mg BID 60 tablets 150 mg 2.23 Yes P Yes Yes
Rivaroxaban 20 mg QD 28 tablets 20 mg 2.20 Yes P Yes No
Edoxaban 60 mg QD 28 tablets 60 mg 2.09 Yes A Yes No
Warfarin 5 mg QD 30 tablets 5 mg 0.071 ‑ ‑ ‑ ‑
Table iii. Drug acquisition costs (prices refer to 2016)
1 Retail price
A = At the time of the acquisition; P = Returned as payback
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riod. Among DOACs, apixaban, with 336 stroke/SE and 728 major bleeding events avoided, 
showed the highest clinical benefit, followed by edoxaban 60 mg, and dabigatran 150 mg, 
while rivaroxaban, according to the methodology used and the outcomes considered, would 
not seem to have a net clinical benefit, as defined for the purpose of the present analysis, over 
warfarin.
Table IV reports the incremental costs as-
sociated with each DOAC vs. warfarin. The 
higher drug acquisition cost associated with 
apixaban, compared with other DOACs, is 
coupled with the lowest incidence of clinical 
events, resulting in the least cost per avoided 
event (Figure 3).
sensitivity analysis
Figure 4 shows the results of the PSA 
in terms of cost-effectiveness acceptability 
curve (CEAC).
dIscussIon
In the last years warfarin was progres-
sively substituted by DOACs as anticoagu-
lant therapy for the prevention of stroke in 
patients with NVAF. In pivotal RCTs, DO-
ACs have demonstrated net clinical benefit 
compared with warfarin, mainly driven by 
Figure 2. Number of Clinical Events Avoided vs. warfarin (negative values indicate increased number of events with the treatment 
compared to warfarin)
Costs (€)1 net clinical benefit
Event‑related Drug Monitoring avoided events (n.) Cost per avoided event (€)
Apixaban vs. warfarin ‑6,360,441 62,092,500 ‑38,000,000 1,064 16,672
Dabigatran vs. warfarin ‑6,142,135 59,535,750 ‑38,000,000 428 35,924
Edoxaban vs. warfarin ‑3,791,737 56,613,750 ‑38,000,000 615 24,120
Rivaroxaban vs. 
warfarin
‑1,291,714 56,613,750 ‑38,000,000 ‑139 N/A
Table iV. Net costs and net clinical benefit of DOACs vs. warfarin
1 Negative values indicate savings with the treatment compared to warfarin
Figure 3. Incremental cost per avoided event (vs. warfarin). The graph does not 
show the result for rivaroxaban, as its cost per avoided event resulted negative 
(dominated)
Figure 4. Cost-effectiveness acceptability curve
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a significant reduction of intracranial bleedings [6-9]. However, relevant differences in the 
incidence of major and gastrointestinal bleeding have been observed among DOACs, and 
apixaban seems to have the best safety profile, with a lower incidence of major bleeding [10-
12] including gastrointestinal bleeding [13,14].
The economic value of apixaban has been demonstrated in an independent cost-effec-
tiveness analysis conducted in UK and based on the data from a network meta-analysis of 23 
RCTs [12], which showed that apixaban has a slightly higher expected quality-adjusted life 
expectancy (QALYs: 5.49 vs. 5.45 of rivaroxaban, 5.42 of dabigatran 150 mg, and 5.41 of 
edoxaban 60 mg) and the highest probability of being the most cost-effective first-line therapy 
for AF (close to 60% for willingness to pay thresholds of £ 20,000-30,000). In a systematic 
review on the cost-effectiveness of apixaban for stroke prevention, which included 23 cost-
effectiveness studies from 14 countries, apixaban appears to be more cost-effective than war-
farin and other DOACs [27].
In particular, apixaban was cost-effective compared to warfarin according to the cost-
effectiveness thresholds used in various countries, furthermore all the studies indicated that 
apixaban was cost-effective, or dominant, with ICERs below the WTP thresholds. The eco-
nomic evaluations showed a mean ICER equal to 16,502 €/QALY (7,212-57,245 €/QALY) 
and the probability of apixaban to be cost-effective equal to 73.4%.
The evaluation of the net clinical benefit allows balancing efficacy (in terms of reduction 
of ischemic stroke and systemic embolism) and risk (in terms of hemorrhagic events) of the 
anticoagulant therapy with DOACs vs. warfarin and, in the absence of direct comparisons, 
may help clinical decisions.
In the present analysis, which aimed to evaluate the costs associated with the prevention 
of stroke/SE and major bleeding in adult patients with NVAF, apixaban was associated with 
1,064 avoided events over 1 year (728 major bleeding events and 336 strokes/SE), the highest 
net clinical benefit compared to warfarin among considered DOACs. Furthermore, apixaban 
was found to be the most efficient DOAC, with the lower incremental cost per avoided event 
equal to € 16,672 vs. warfarin. Finally, the results of the PSA shown that apixaban had the 
highest chances to be the most cost-effective treatment for any WTP thresholds higher than € 
5,000 per avoided event.
However, equaling the relevance of all clinical events may be a limitation of the meth-
odology we used to estimate the net clinical benefit: as previously pointed out, an approach 
weighting the number of events by event-specific clinical relevance tariffs may be more ac-
curate in reflecting the global clinical balance among avoided ischemic events and potential 
excess bleeds [28-31].
A recent Italian research aimed to estimate the net clinical benefit of DOACs vs. warfarin 
based on data from phase III clinical trials [31] applied this weighing approach to assess the 
net clinical benefit of the DOACs, as compared to warfarin, in AF patients. The results of this 
analysis are in agreement with our unadjusted approach in terms of ranking among DOACS, 
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with apixaban showing the highest net clinical benefit, followed by edoxaban, dabigatran, and 
rivaroxaban [31]. However, a notable difference refers to rivaroxaban, that also outperforms 
warfarin when the net clinical benefit is estimated using the weighed approach. When we 
repeated our analysis using as input the net clinical benefit reported by Renda et al. [31], our 
conclusions were unaffected: apixaban is the most efficient DOAC, with a cost per avoided 
event equal to € 13,038 vs. warfarin (€ 14,252 for edoxaban 60 mg, € 15,092 for dabigatran 
150 mg, and € 23,408 for rivaroxaban).
Another possible limitation of our analysis is the deterministic use of the central estimate 
of the HRs calculated by Lip et al. [18]; however, the consistence of the results obtained using 
two different sources as clinical input strengthens our confidence in the main conclusion of 
the analyses.
A caveat needed in interpreting our results is inherent to the type of comparison feeding 
the clinical side of the analyses, i.e. indirect comparison – full validity can be claimed for 
the comparisons of the single DOACs vs. warfarin, in the specific population of AF patients 
evaluated in the pivotal RCTs, while the comparisons among the former are valid to the extent 
to which these populations can be regarded as comparable.
Two more limitations to be kept in mind are common to all model-based economic evalua-
tions, and relate to the need to combine different sources in one single conceptual framework, 
and to the limited transferability of the economic result from one setting to others – these 
results are Italy specific.
conclusIons
Several studies and meta-analyses suggest that apixaban has the highest potential net clini-
cal benefit among DOACs for patients with NVAF. Our findings demonstrate that the higher 
drug acquisition cost associated with apixaban is coupled with the lowest incidence of clinical 
events, resulting in the least incremental cost per avoided event from the perspective of the 
Italian health service.
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AppendIx A
Event
Expected 
value1
Distribution 
type
Mean sE2
apixaban vs. warfarin
Stroke/SE ‑0,236 Normal ‑0,236 0,357
Major bleeding ‑0,371 Normal ‑0,371 0,282
Hemorragic stroke ‑0,673 Normal ‑0,673 0,734
Dabigatran vs. warfarin
Stroke/SE ‑0,431 Normal ‑0,431 0,434
Major bleeding ‑0,073 Normal ‑0,073 0,273
Hemorragic stroke ‑1,347 Normal ‑1,347 1,280
rivaroxaban vs. warfarin
Stroke/SE ‑0,139 Normal ‑0,139 0,324
Major bleeding 0,049 Normal 0,049 0,271
Hemorragic stroke ‑0,528 Normal ‑0,528 0,809
Edoxaban vs. warfarin
Stroke/SE ‑0,139 Normal ‑0,139 0,301
Major bleeding ‑0,223 Normal ‑0,223 0,243
Hemorragic stroke ‑0,598 Normal ‑0,598 0,679
Table ia. Parameters and distributions used for the PSA
1 These values represent the natural logarithm of reported HRs
2 Obtained from reported CI95%
